Security Snapshot

ARROWHEAD PHARMACEUTICALS, INC. - COMMON STOCK (ARWR) Institutional Ownership

CUSIP: 04280A100

13F Institutional Holders and Ownership History from Q4 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

375

Shares (Excl. Options)

76.62MFull value: 76,616,551 · shares · 30 Sep 2026

Price

$65.45

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+236,470
Value change
-$21,685,764
Number of holders
375
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
141,020,453
SEC-reported price per share
$61.48
Insider filing price
$61.48
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ARWR - ARROWHEAD PHARMACEUTICALS, INC. - COMMON STOCK is tracked under CUSIP 04280A100.
  • 375 institutions reported positions in Q3 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 502 to 375 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $9.74BFull value: $9,738,452,464 · USD · 30 Jun 2026
    to
    $5.02BFull value: $5,021,390,070 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 375 institutions filings for Q3 2026.

Open SEC evidence

Security key

04280A100

13F reference period

Q3 2026

13F holders

375

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
ARWR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 10% -18% $1,160,094,743 -$234,059,144 14,232,545 -17% BlackRock, Inc. 30 Jun 2026
Avoro Capital Advisors LLC 9.6% +17% $1,202,219,620 +$200,547,776 13,823,383 +20% Avoro Capital Advisors LLC 30 Jun 2026
FMR LLC 6.6% +28% $572,215,871 +$120,392,780 9,307,350 +27% FMR LLC 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5% $443,997,071 7,081,293 Vanguard Capital Management 31 Mar 2026
VANGUARD PORTFOLIO MANAGEMENT LLC 4.5% -13% $555,295,014 -$76,973,146 6,384,903 -12% Vanguard Portfolio Management 30 Jun 2026
STATE STREET CORP 4.6% -10% $106,970,030 -$10,547,360 6,371,056 -9% STATE STREET CORPORATION 30 Jun 2025
As of 30 Sep 2026, 375 institutional investors reported holding
76.62MFull value: 76,616,551 · shares · 30 Sep 2026
shares of ARROWHEAD PHARMACEUTICALS, INC. - COMMON STOCK (ARWR). This represents 54% of the company’s total
141.02MFull value: 141,020,453 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
42%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Avoro Capital Advisors LLC 7.8% 11,000,000 7.4% $719,950,000
VANGUARD PORTFOLIO MANAGEMENT LLC 4.4% 6,210,955 0.02% $406,507,005
STATE STREET CORP 4.3% 6,122,271 0.01% $400,702,637
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 6,118,719 0.01% $400,470,159
Vestal Point Capital, LP 3.4% 4,815,000 8.1% $315,141,750
Invesco Ltd. 2.7% 3,825,146 0.02% $250,355,806
GEODE CAPITAL MANAGEMENT, LLC 2.5% 3,458,467 0.01% $234,498,352
Siren, L.L.C. 1.6% 2,290,476 3.6% $149,911,654
BAKER BROS. ADVISORS LP 1.2% 1,709,053 0.53% $111,857,519
Janus Henderson Group Ltd. 0.96% 1,346,984 0.04% $88,207,247
Hood River Capital Management LLC 0.8% 1,130,508 0.63% $73,991,749
TWO SIGMA INVESTMENTS, LP 0.77% 1,083,432 0.05% $70,910,624
DIMENSIONAL FUND ADVISORS LP 0.76% 1,069,701 0.01% $70,013,279
BANK OF AMERICA CORP /DE/ 0.67% 941,597 0% $61,627,518
VANGUARD FIDUCIARY TRUST CO 0.64% 902,211 0.01% $59,049,710
Fisher Asset Management, LLC 0.63% 893,700 0.02% $58,492,677
GOLDMAN SACHS GROUP INC 0.6% 848,997 0.01% $55,566,871
DEERFIELD MANAGEMENT COMPANY, L.P. 0.6% 843,063 0.85% $55,178,473
Western Financial Corp/CA 0.58% 820,239 18% $53,684,643
Driehaus Capital Management LLC 0.58% 812,418 0.37% $53,172,758
Pictet Asset Management Holding SA 0.54% 767,192 0.05% $50,212,716
Connor, Clark & Lunn Investment Management Ltd. 0.31% 437,210 0.05% $28,615,395
Affinity Asset Advisors, LLC 0.3% 425,000 1.6% $27,816,250
Aberdeen Group plc 0.29% 413,104 0.04% $27,037,657
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.28% 400,546 0.02% $26,215,736

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
48
Headline period
Q3 2026
Rows shown
1-25 of 48
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 76,616,551 $5,021,390,070 -$21,685,764 $65.45 375
2026 Q2 119,398,928 $9,738,452,464 -$54,295,806 $81.51 502
2026 Q1 120,841,602 $7,577,172,679 +$294,677,552 $62.70 437
2025 Q4 115,966,805 $7,699,721,958 +$347,241,347 $66.39 400
2025 Q3 110,897,224 $3,823,917,269 +$261,693,126 $34.49 300
2025 Q2 105,716,035 $1,671,181,802 +$44,748,514 $15.80 279
2025 Q1 103,362,113 $1,318,228,654 +$23,656,546 $12.74 258
2024 Q4 99,701,045 $1,874,384,692 +$32,738,534 $18.80 267
2024 Q3 97,715,477 $1,892,897,060 -$93,908,485 $19.37 267
2024 Q2 97,822,928 $2,542,052,894 +$57,202,679 $25.99 272
2024 Q1 96,658,787 $2,763,026,175 +$544,741,705 $28.60 267
2023 Q4 77,504,804 $2,371,960,338 +$86,943,186 $30.60 265
2023 Q3 74,643,254 $2,005,663,054 +$41,168,266 $26.87 253
2023 Q2 71,799,685 $2,559,646,627 -$10,508,327 $35.66 267
2023 Q1 72,976,301 $1,851,849,623 -$23,671,296 $25.40 250
2022 Q4 73,474,031 $2,977,955,799 +$97,292,640 $40.56 276
2022 Q3 71,284,086 $2,353,949,365 -$40,859,478 $33.05 264
2022 Q2 72,095,607 $2,538,257,759 +$100,531,936 $35.21 263
2022 Q1 69,254,530 $3,184,523,615 +$35,685,819 $45.99 294
2021 Q4 67,961,552 $4,505,834,422 +$55,872,415 $66.30 297
2021 Q3 66,549,683 $4,154,048,742 -$66,618,101 $62.43 282
2021 Q2 66,896,948 $5,539,659,575 -$140,144,186 $82.82 304
2021 Q1 68,464,454 $4,541,675,803 -$29,602,424 $66.31 281
2020 Q4 69,478,160 $5,331,874,119 +$80,806,659 $76.73 302
2020 Q3 68,146,322 $2,935,188,814 -$17,523,513 $43.06 252
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .